Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
City of Hope Medical Center Identifier:
First received: January 6, 2005
Last updated: October 4, 2013
Last verified: October 2013

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of IH636 grape seed extract may prevent breast cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of IH636 grape seed extract in preventing breast cancer in postmenopausal women at risk of developing breast cancer.

Condition Intervention Phase
Breast Cancer
Dietary Supplement: IH636 grape seed proanthocyanidin extract
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer

Resource links provided by NLM:

Further study details as provided by City of Hope Medical Center:

Primary Outcome Measures:
  • Estrogen suppression as measured by serum estradiol, estrone, estrone sulfate, and sex hormone binding globulin [ Time Frame: at 1, 2, 4, 8, and 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Androgenic effects as measured by serum testosterone, androstenedione, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEAS) [ Time Frame: at 1, 2, 4, 8, and 12 weeks ] [ Designated as safety issue: No ]
  • Lipid effects as measured by total cholesterol, LDL, HDL, and triglycerides [ Time Frame: at 12 weeks ] [ Designated as safety issue: No ]
  • Bone metabolic effects as measured by bone-specific alkaline phosphatase and N-telopeptides [ Time Frame: at 12 weeks ] [ Designated as safety issue: No ]
  • Insulin regulatory effects as measured by insulin-like growth factor 1 (IGF1) and insulin-like growth factor-binding protein 3 (IGFBP3) [ Time Frame: at 12 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetics as measured by procyanidins [ Time Frame: before and after first dose and then at 1, 2, 4, 8, and 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 37
Study Start Date: January 2005
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dietary Supplement: grape seed proanthocyanidin extract
Administered orally.
Dietary Supplement: IH636 grape seed proanthocyanidin extract
Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage

Detailed Description:


  • Determine the efficacy of IH636 grape seed proanthocyanidin extract, in terms of suppression of estrogen biosynthesis, in healthy post-menopausal women at high risk of developing breast cancer.
  • Determine the safety and tolerability of this dietary supplement, in terms of symptoms and changes in markers of bone and lipid metabolism and in markers of nonspecific adrenal suppression, in these participants.
  • Determine, preliminarily, an optimum biologic dose of this dietary supplement, as defined by suppression of serum estradiol, in these participants.
  • Determine a minimum duration of use of this dietary supplement to achieve aromatase inhibition in these participants.

OUTLINE: This is a pilot, dose-finding, placebo-controlled study.

Participants receive oral placebo once or twice daily on days -14 to 0. Participants then receive oral IH636 grape seed proanthocyanidin extract once or twice daily on days 1-85. Treatment continues in the absence of toxicity.

Cohorts of 6 participants receive one of four dose levels of IH636 grape seed proanthocyanidin extract up to an established safe dose.

PROJECTED ACCRUAL: A total of 24 participants will be accrued for this study within 12 months.


Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes


  • At risk of developing breast cancer
  • No history of breast cancer or ductal carcinoma in situ



  • 40 to 75


  • Female

Menopausal status

  • Postmenopausal, defined by 1 of the following criteria:

    • No spontaneous menses for ≥ 12 months
    • Prior bilateral oophorectomy
    • Prior hysterectomy with follicle-stimulating hormone within menopausal range

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • Hemoglobin ≥ 9.0 g/dL
  • Platelet count ≥ 100,000/mm^3
  • WBC ≥ 3,500/mm^3
  • Absolute granulocyte count ≥ 1,500/mm^3
  • No coagulation disorders


  • SGOT and SGPT ≤ 2 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN


  • Creatinine ≤ 1.5 times ULN


  • No major illness of the cardiovascular system


  • No major illness of the respiratory system


  • No history of other invasive cancer within the past 5 years except squamous cell or basal cell skin cancer
  • No major systemic infection
  • No Cushing's syndrome or adrenal insufficiency
  • No osteoporosis, defined as a bone mineral density T-score ≥ -2.5 on dual-energy x-ray absorptiometry scan (calcium and/or cholecalciferol [vitamin D] supplementation AND/OR bisphosphonate therapy allowed provided participant is on a stable dose during study participation)


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • More than 3 months since prior hormone-modifying medications, including any of the following:

    • Oral contraceptives
    • Hormone replacement therapy
    • Selective estrogen receptor modifiers
    • Aromatase inhibitors
    • Gonadotropin-releasing hormone modifiers
  • Concurrent dehydroepiandrosterone (DHEA) allowed, provided dose remains constant during study participation


  • Not specified


  • Not specified


  • No red wine, red grapes, or white button mushrooms directly before or during study treatment

    • White and seedless grapes allowed
  • No other concurrent therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00100893

United States, California
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010-3000
Sponsors and Collaborators
City of Hope Medical Center
  More Information

Additional Information:
No publications provided

Responsible Party: City of Hope Medical Center Identifier: NCT00100893     History of Changes
Other Study ID Numbers: 03178, P30CA033572, CHNMC-IRB-03178, CDR0000407637
Study First Received: January 6, 2005
Last Updated: October 4, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by City of Hope Medical Center:
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Grape Seed Extract
Anti-Infective Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiparasitic Agents
Antiprotozoal Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses processed this record on November 25, 2014